What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cannabinoid
- Gene
His primary areas of study are Cannabinoid, Cannabinoid receptor, Pharmacology, Cannabinoid receptor type 2 and Cannabinoid Receptor Agonists.
His Cannabinoid research incorporates elements of Agonist, Anandamide, Stereochemistry and Endocannabinoid system.
His biological study spans a wide range of topics, including Endocrinology, Cannabinol and Neuroscience.
The various areas that Roger G. Pertwee examines in his Pharmacology study include Cannabinoid Receptor Modulators, Tetrahydrocannabivarin, Cannabidiol, Cannabis and GPR18.
The study incorporates disciplines such as Immunology, Molecular biology and AM251 in addition to Cannabinoid receptor type 2.
His Cannabinoid Receptor Agonists research integrates issues from Cannabinoid receptor antagonist and URB597.
His most cited work include:
- ISOLATION AND STRUCTURE OF A BRAIN CONSTITUENT THAT BINDS TO THE CANNABINOID RECEPTOR (4525 citations)
- Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. (2333 citations)
- International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors (2187 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Cannabinoid, Pharmacology, Cannabinoid receptor, Cannabinoid receptor type 2 and Receptor.
The Cannabinoid study combines topics in areas such as Agonist, Anandamide, Endocrinology and Stereochemistry.
His research investigates the connection between Pharmacology and topics such as Cannabidiol that intersect with problems in Neuroprotection.
His Cannabinoid receptor research includes elements of Inverse agonist and Endocannabinoid system.
Roger G. Pertwee has researched Endocannabinoid system in several fields, including Allosteric modulator and Neuroscience.
The various areas that Roger G. Pertwee examines in his Cannabinoid receptor type 2 study include Cannabinoid Receptor Modulators and AM251.
He most often published in these fields:
- Cannabinoid (53.50%)
- Pharmacology (52.23%)
- Cannabinoid receptor (51.27%)
What were the highlights of his more recent work (between 2012-2021)?
- Cannabinoid receptor (51.27%)
- Pharmacology (52.23%)
- Cannabinoid (53.50%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Cannabinoid receptor, Pharmacology, Cannabinoid, Receptor and Endocannabinoid system.
His study in Cannabinoid receptor focuses on Cannabinoid Receptor Agonists, Anandamide and Cannabinoid receptor antagonist.
His Pharmacology study integrates concerns from other disciplines, such as Tetrahydrocannabivarin, Allosteric regulation, Cannabidiol and Receptor antagonist.
His research in Cannabinoid intersects with topics in Allosteric modulator, Endocrinology, Regulatory sequence and Cannabinoid receptor type 2.
He combines subjects such as Stereochemistry and In vivo with his study of Receptor.
His Endocannabinoid system study also includes
- Neuroscience which connect with Pain management,
- URB597, JZL184, Cannabinoid Receptor Modulators and Cannabinoid receptor type 1 most often made with reference to Rimonabant.
Between 2012 and 2021, his most popular works were:
- Are cannabidiol and Δ9‐tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review (269 citations)
- Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? (178 citations)
- Early phytocannabinoid chemistry to endocannabinoids and beyond (167 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Gene
- Biochemistry
Roger G. Pertwee focuses on Pharmacology, Cannabinoid receptor, Cannabinoid, Endocannabinoid system and Receptor.
His biological study spans a wide range of topics, including Dopaminergic, Cannabidiol, Metabotropic receptor, Cannabinoid receptor type 1 and In vivo.
His research in Cannabinoid receptor type 2, Cannabinoid Receptor Agonists and Cannabinoid receptor antagonist are components of Cannabinoid receptor.
Roger G. Pertwee interconnects Depolarization-induced suppression of inhibition, Virodhamine and GPR18 in the investigation of issues within Cannabinoid Receptor Agonists.
Cannabinoid is a subfield of Internal medicine that he studies.
His Agonist and Cannabidiolic acid study in the realm of Receptor interacts with subjects such as Cannabis sativa.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
